A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Inclusion Criteria: 1. Voluntary participation in the clinical trial; fully understand, be informed about this study and have signed the ICF; willing to follow and able to complete all study procedures; 2. Aged 18 to 79 years; 3. Histologically confirmed pancreatic ductal adenocarcinoma; 4. Macroscopic complete tumor removal (R0 or R1 resection); 5. Postoperative pathological stage (pTNM): T1-3, N0-2, M0; 6. Immunohistochemistry (IHC) staining of subject's tumor tissue sample is CLDN18.2-positive; 7. Subjects had recovered from surgery and had received 3 months of standard adjuvant therapy; 8. Abnormal CA19-9 level; 9. With sufficient venous access for leukapheresis collection; 10. ECOG performance status score 0-1; 11. Adequate organ function; 12. Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy; Exclusion Criteria: 1. Prior neoadjuvant therapy for pancreatic cancer; 2. Subjects with borderline resectable pancreatic cancer; 3. Present or past history of metastatic or locally recurrent pancreatic cancer; 4. Evidence of malignant ascites; 5. Subjects had diseases that may interfere with CA19-9 level, including but not limited to cholangitis, pancreatitis, obstructive jaundice, etc. 6. Toxicities caused by previous treatment have not recovered to CTCAE ≤ grade 2, except alopecia and other tolerable events as judged by the investigator or laboratory abnormalities allowed in this study; 7. Pregnant or lactating women; 8. Positive serology for HIV, Treponema pallidum or HCV; 9. Any active infections, including but not limited to active tuberculosis, HBV, EBV, CMV, COVID-19 infections; 10. Clinically significant thyroid dysfunction; 11. Previous allergy to immunotherapy and related drugs, allergy to CT041 ingredients and other serious allergic history; 12. Subjects who may be at high risk for potential digestive tract bleeding or perforation; 13. Known active autoimmune disease, including but not limited to, psoriasis or rheumatoid arthritis, or other conditions requiring long-term immunosuppressive therapy; 14. Subjects who have a history of organ transplantation or are awaiting organ transplantation; 15. Subjects who require anticoagulant therapy; 16. Subjects who are receiving or are expected to require long-term antiplatelet therapy during the study; 17. Subjects who have experienced major surgery or have significant trauma within 4 weeks before apheresis, or who are expected to undergo major surgery during the study period; 18. Previously received any gene-modified cell therapies (including CAR T, TCR T); 19. Subjects who have other serious diseases that may restrict them from participating in the study assessed by investigators; 20. Subjects with oxygen saturation ≤ 95%; 21. Subjects who have signs of central nervous system diseases or clinically significant neurological examination abnormalities; 22. Subjects who have other uncured malignant tumors in the past 3 years or at the same time, except those with very low degree of malignancy such as cervical cancer in situ and basal cell carcinoma of skin; 23. Vaccination with live attenuated vaccines within 4 weeks prior to apheresis or planned during the study; 24. Subjects who are unable to or unwilling to comply with the requirements of the study protocol as assessed by investigators.